Obstructive Pulmonary Disease
Conditions
Brief summary
Discovery of the pathogenesis and targets in the progression of early chronic obstructive pulmonary disease
Detailed description
This project is aimed to investigate and explore the heterogeneity during the progression of Chronic Obstructive Pulmonary Disease (COPD) in the early stage, utilizing the large-scale population cohort databases (including China Pulmonary Health study, The Cohort Study for Chronic Obstructive Pulmonary Disease in China and Acute Exacerbation of COPD Patient Registry in China ), biological sample libraries(including blood, sputum, expiratory air, bronchoalveolar lavage fluid(BALF), and lung tissue from COPD patients with different stages and phenotypes), and multi-omics sequencing (including scRNA-seq, metabolomics, proteomics, and metagenome). We propose to establish a new standard for COPD stages and subtypes. By analyzing and mining the multi-omics data, it is expected to illustrate the association between clinical phenotype and molecular, cellular and tissue heterogeneities, thus reveal biomarkers related to the progression, clinical phenotypes, and prognosis of early-stage COPD disease.In addition, we will construct different types and stages of COPD animal models for further mechanism studies, such as the different pathogenic factors, innate and adaptive immunity, and the airway microbial ecosystem, so that we can discovered more potential therapeutic target for early-stage COPD. This project can bring a new insight and scientific evidence for COPD treatment.
Interventions
None listed
Sponsors
Chinese Academy of Medical Sciences
Second Affiliated Hospital, School of Medicine, Zhejiang University
Capital Medical University
Peking University Third Hospital
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
China-Japan Friendship Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* younger than 50 years * smoking more than 10 pack-years * early airflow limitation(post-bronchodilator FEV1/FVC\< lower limit of normal)
Exclusion criteria
* cancer * other respiratory diseases * mental illness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| FEV1 annual decline in clinical practice | 2021.1-2024.12 | FEV1 measured by portable spirometry can reflect the progression of early COPD. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| dyspnea symptoms | 2021.1-2024.12 | Severity of dyspnea is positively correlated with COPD severity. |
| frequency of COPD acute exacerbation | 2021.1-2024.12 | The frequency of COPD acute exacerbation refers to the number of acute exacerbations per year. |
| chest imaging changes | 2021.1-2024.12 | Emphysema and obstruction in small airway will be evaluated by chest computed tomography(CT). |
| systemic complications | 2021.1-2024.12 | Whether there are systemic complications is related to the prognosis of patients. |
Countries
China
Contacts
Primary ContactChen Wang
Outcome results
None listed